Logo

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

Share this

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

Shots:

  • In the P-I SPICE study- the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types
  • PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21
  • NG-641 is a tumor re-engineering product using PsiOxus’ T-SIGn platform based upon the enadenotucirev vector while Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s own immune system to help restore anti-tumor immune response

  Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions